Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SEQUENT | NSE
-5.29
-2.97%
Healthcare
Drug Manufacturers-Specialty & Generic
31/03/2024
19/09/2024
172.56
179.00
180.87
168.40
Sequent Scientific Limited engages in the animal health business worldwide. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics anti-protozoal nutraceuticals nonsteroidal anti-inflammatory drugs anti-infectives and dermatology. It offers analytical solutions that supports API pharmaceutical personal care and nutraceutical organizations as well as provides method validation stability and microbiology for APIs and finished products. The company was formerly known as PI Drugs and Pharmaceuticals Limited and changed its name to Sequent Scientific Limited in October 2009. Sequent Scientific Limited was incorporated in 1985 and is headquartered in Mumbai India. Sequent Scientific Limited is a subsidiary of CA Harbor Investments.
View LessLow Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
30.5%1 month
36.7%3 months
48.9%6 months
50.7%774.74
33.33
6.76
0.74
0.32
91.18
3.56
-
1.19B
43.09B
515.34M
-
6.79
-44.80
17.10
-4.05
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
16.30
Range1M
26.69
Range3M
68.30
Rel. volume
0.51
Price X volume
354.00M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Hikal Limited | HIKAL | Drug Manufacturers-Specialty & Generic | 376.45 | 46.42B | -1.06% | 72.22 | 68.84% |
Morepen Laboratories Limited | MOREPENLAB | Drug Manufacturers-Specialty & Generic | 83.79 | 45.91B | -3.43% | 40.71 | 3.42% |
Unichem Laboratories Limited | UNICHEMLAB | Drug Manufacturers-Specialty & Generic | 640.75 | 45.33B | -1.94% | n/a | 10.48% |
Gufic Biosciences Limited | GUFICBIO | Drug Manufacturers-Specialty & Generic | 400.45 | 40.16B | 0.33% | 46.93 | 62.51% |
Alembic Limited | ALEMBICLTD | Drug Manufacturers-Specialty & Generic | 139.83 | 35.91B | -2.66% | 14.02 | 0.42% |
Indoco Remedies Limited | INDOCO | Drug Manufacturers-Specialty & Generic | 369.45 | 34.18B | -0.18% | 46.10 | 60.54% |
Suven Life Sciences Limited | SUVEN | Drug Manufacturers-Specialty & Generic | 147.06 | 32.07B | -5.60% | n/a | 0.26% |
SOLARA | SOLARA | Drug Manufacturers-Specialty & Generic | 736.35 | 31.74B | -0.88% | n/a | 107.90% |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | Drug Manufacturers-Specialty & Generic | 481.9 | 28.30B | -4.04% | 25.17 | 2.03% |
Themis Medicare Limited | THEMISMED | Drug Manufacturers-Specialty & Generic | 258.3 | 23.81B | -0.25% | 49.52 | 25.36% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
V2 Retail Limited | V2RETAIL | Apparel Retail | 1134.25 | 39.23B | -1.22% | 133.29 | 191.28% |
"SAI SILKS (KALAMANDIR) LIMITED " | KALAMANDIR | Apparel Retail | 180.19 | 26.57B | -1.78% | 29.68 | 43.67% |
Vertoz Advertising Limited | VERTOZ | Advertising Agencies | 29.97 | 25.67B | -5.01% | 82.05 | 10.74% |
Signpost India Limited | SIGNPOST | Advertising Agencies | 227.91 | 23.45B | -0.74% | n/a | 80.30% |
Bhagyanagar India Ltd | BHAGYANGR | Copper | 102.27 | 3.27B | -3.96% | 34.15 | 52.08% |
Touchwood Entertainment Limited | TOUCHWOOD | Advertising Agencies | 166.42 | 1.85B | -3.27% | 49.20 | 4.88% |
Cubex Tubings Limited | CUBEXTUB | Copper | 93.74 | 1.34B | -3.01% | 34.07 | 21.78% |
Madhav Copper Limited | MCL | Copper | 36.42 | 1.02B | -1.33% | n/a | 32.70% |
Sagardeep Alloys Limited | SAGARDEEP | Copper | 28.12 | 483.23M | 88.75 | 43.14% | |
Heads UP Ventures Limited | HEADSUP | Apparel Retail | 14.67 | 331.86M | -1.48% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 91.18 | 23.29 | Expensive |
Ent. to Revenue | 3.56 | 12.02 | Cheaper |
PE Ratio | 774.74 | 47.84 | Expensive |
Price to Book | 6.76 | 6.55 | Par |
Dividend Yield | - | 0.59 | - |
Std. Deviation (3M) | 48.89 | 40.95 | Par |
Debt to Equity | 0.74 | 0.34 | Expensive |
Debt to Assets | 0.32 | 0.17 | Expensive |
Market Cap | 43.09B | 286.13B | Emerging |